CytomX Therapeutics to Present at Upcoming November Investor Conferences
11 Noviembre 2021 - 7:00AM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the
field of conditionally activated therapeutics, today announced that
Sean McCarthy, D.Phil., president, chief executive officer, and
chairman, will participate in virtual fireside chats at the
following investor conferences in November.
12th
Annual Jefferies Global Healthcare ConferenceDate:
Thursday, November 18, 2021
33rd
Annual Piper Sandler Virtual Healthcare
ConferenceDate: Tuesday, November 30, 2021
The Jefferies fireside chat will be made
available at 3:00 a.m. ET (8:00 a.m. GMT) on Thursday, November 18,
2021 on the Events and Presentations page of CytomX’s website at
www.cytomx.com. The Piper Sandler fireside chat will be made
available at 10:00 a.m. ET on Monday, November 22, 2021. Archived
replays of both fireside chats will be available on the CytomX
website for 30 days following the event. In addition, management
will be available for one-on-one meetings with investors who are
registered to attend the conferences.
About CytomX Therapeutics,
Inc.CytomX is a clinical-stage, oncology-focused
biopharmaceutical company dedicated to destroying cancer
differently. By pioneering a novel class of conditionally activated
biologics, powered by its Probody® technology platform, CytomX’s
goal is to transcend the limits of current cancer treatments and
successfully leverage therapeutic targets that were once thought to
be inaccessible. CytomX’s robust and differentiated pipeline
includes the wholly-owned praluzatamab ravtansine (CX-2009), an
investigational conditionally activated antibody-drug conjugate
(ADC) directed toward CD166, and CX-2029, an investigational
conditionally activated ADC directed toward CD71 co-developed with
AbbVie. These two programs are currently being evaluated in Phase 2
studies, targeting a variety of late-stage, difficult-to-treat
cancer types, including breast cancer for praluzatamab ravtansine,
and squamous non-small cell lung cancer, and head and neck squamous
cell carcinoma for CX-2029. CytomX’s clinical pipeline also
includes cancer immunotherapeutic candidates against validated
targets such as the CTLA-4-targeting Probody therapeutics,
BMS-986249 and BMS-986288, partnered with Bristol Myers Squibb, and
our wholly-owned conditionally activated anti-PD-L1 antibody,
pacmilimab (CX-072). In addition, CytomX has a diverse preclinical
portfolio and strategic collaborations with other leaders in
oncology, including AbbVie, Amgen, Astellas, and Bristol Myers
Squibb. For more information about CytomX and how it is working to
make conditionally activated treatments the new standard-of-care in
the fight against cancer, visit www.cytomx.com and follow us on
LinkedIn and Twitter.
Probody is a U.S. registered trademark of CytomX
Therapeutics, Inc.
Investor Contact:Chau Cheng,
PhD MBAVP, Investor Relations & Corp.
Communicationsccheng@cytomx.comDirect: (650) 273-4999
Media Contact:Bret
CoonsDirector, Corporate Communicationsbcoons@cytomx.comDirect:
(650) 528 2929
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024